Novo Nordisk chairman on lacking diversity: "I haven't done enough"

Novo Nordisk's own chairman still thinks a massive effort is needed to achieve the optimal gender balance within the company, and he turns the criticism for lacking results inward.

Novo Nordisk President and CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH

Gender diversity is not where it should be at Novo Nordisk, even though the pharmaceutical giant has launched a series of diversity initiatives from the viewpoint of the firm's Chairman of the Board Helge Lund, according to newspaper Børsen.

"For many years I took for granted that women and men had equal opportunities, and I was pretty relaxed about gender, but looking back, I was probably too relaxed, and over the years I have discovered that as a leader I have not done enough," Lund stated on a Thursday video connection at an annual board summit organized by the Danish Chamber of Commerce (Dansk Erhverv, -ed.), Axcel Future and the Board Leadership Society (bestyrelsesforeningen, -ed.)

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs